SARS-CoV-2 Omicron symptoms and adverse effects of GLP-1 RA therapy.

Journal Information

Full Title: Acta Diabetol

Abbreviation: Acta Diabetol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Endocrinology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestM.J. has given lectures, received honoraria, participated in conferences and advisory boards sponsored by pharmaceutical companies including Amgen, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Novartis and Servier. A.J. has served as a consultant and is on Speakers Bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, MerckSharp & Dohme (MSD), Novo Nordisk, Medtronic and Sanofi. None of the above had any role in this article, which has been written independently, without any financial or professional help, and reflects only the authors' opinion, without any role of the industry. T.B. is supported in part by the Slovenian Research Agency grant # P3-0343. No potential conflicts of interest relevant to this article were reported. Human and animal rightsOur study has been reviewed by the national ethics committee and has been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. Informed consentAll persons gave their informed consent prior to their inclusion in the study. Conflict of interest M.J. has given lectures, received honoraria, participated in conferences and advisory boards sponsored by pharmaceutical companies including Amgen, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Novartis and Servier. A.J. has served as a consultant and is on Speakers Bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, MerckSharp & Dohme (MSD), Novo Nordisk, Medtronic and Sanofi. None of the above had any role in this article, which has been written independently, without any financial or professional help, and reflects only the authors' opinion, without any role of the industry. T.B. is supported in part by the Slovenian Research Agency grant # P3-0343. No potential conflicts of interest relevant to this article were reported."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025